BBI Solutions completes reagent manufacturer acquisition

5-Jan-2022

BioTeZ is a manufacturer of reagents and finished tests for the in-vitro diagnostics (IVD) market

Left to right: Damian Evans, Global Head of Quality and Director of Business Integration, BBI Solutions and Mario Gualano, CEO BBI Solutions

BBI Solutions, a provider of immuno-diagnostic reagents and contract services, has announced the acquisition of Biotez Berlin-Buch and Steffens-Biotec.

BioTeZ is a manufacturer of reagents and finished tests for the in-vitro diagnostics (IVD) market, as well as components for the food safety market.

The acquisition of BioTeZ adds capability and enhances BBI’s position as an immunoassay reagent supplier, the company says. For example, the addition of BioTeZ’s Streptavidin-based portfolio enhances the company’s existing IVD Label portfolio with reagents including Polystreptavidin, oligonucleotides and poly HRP.

The addition of immunoassay development services for ELISA and other formats also expands BBI’s existing service offering.

The UK-based business, which has manufacturing sites and sales offices across four continents, will integrate the BioTeZ’s manufacturing facilities in Germany.

BBI Group CEO, Mario Gualano said: “This latest acquisition of BioTeZ and Steffens-Biotec further enhances our portfolio and positions BBI as a leading immunoassay reagent supplier. It enables us to provide additional products and services in the fight against the COVID pandemic. The combined research and development capability will provide customers of both BioTeZ and BBI with new, innovative products and a broader portfolio for greater choice.”

The combined capability enables BBI to further service disease segments such as cancer, diabetes, and non-IVD sectors such as food safety while also driving geographic expansion for BioTeZ and Steffens-Biotec, which will now have a larger sales force.

Sign up for your free email newsletter

Uwe Ahnert, CEO of BioTeZ, said: “We are very proud to become part of the BBI family and to be able to reach many more customers worldwide. In doing so, we will be able to support them in the production and development of innovative diagnostics.”

Companies